Promising results reported from Notal Home OCT feasibility study
A home-based OCT imaging study in patients with wet age-related macular degeneration demonstrated ease of use and good image quality, according to a press release from Notal Vision.
“The results of the first U.S. study confirm the key target product profile requirements of our Home OCT program,” Kester Nahen, PhD, CEO of Notal Vision, said in the release.
In the feasibility study, 15 patients with an average age of 70.4 years used the Notal Home OCT device to produce self-imaged scans over 90 days, totaling 2,374 scans.
The study “showed the device’s ease of use, good image quality, compliant self-imaging and spatiotemporal tracking of retinal fluid in an elderly wet AMD patient population,” the release said.
Quality criteria were met in 93% of scans, enabling the artificial intelligence algorithm to perform fluid quantification, the release said.
The device is in the process of obtaining FDA clearance.